Researcher together with the Milenia Biotech GmbH are developing a diagnostic tool for patients with bone healing problems.
Researcher at the Julius Wolff Institute, the Berlin-Brandenburg Center for Regenerative Therapies and the Center for Musculoskeletal Surgery of the Charité – Universitätsmedizin Berlin together with the Milenia Biotech GmbH are developing a diagnostic tool for patients with bone healing problems. Around 5 to 15 percent of patients suffer from impaired or delayed healing or failure of the bone defect to heal at all. In most cases a second surgery is necessary to administer additional materials such as bone substitutes or substances that stimulate the healing process.
Therefore, scientists are currently developing a diagnostic system that is able to identify patients at risk for a reduced healing capacity during the initial operation. With this tool, the surgical team receives a prognosis about the healing outcome of the patient. Thus, a second surgical operation can be prevented as the necessary treatment can effectively be administered during the first surgery.
The Julius Wolff Institute will realise the project together with the Milenia Biotec GmbH. The biotechnology company from Giessen, Germany, will develop the immunoassay-test that uses the antigen-antibody reaction. The assay will be able to measure the concentration of specific growth factors, cytokines and proteases that play a significant role during the early phase of bone healing. A prior study at the Julius Wolff Institute has already shown that the concentration of these proteins provides an indication of the outcome of patients' bone healing capacity.
The project will be financed through the German Federation of Industrial Research Associations (AiF) with funds from the "Zentralen Innovationsprogramm Mittelstand" (ZIM).
Back to Overview